Cystic Fibrosis Canada
STAR RATINGCi's Star Rating is calculated based on the following independent metrics: |
✔+
FINANCIAL TRANSPARENCY
Audited financial statements for current and previous years available on the charity’s website.
A-
RESULTS REPORTING
Grade based on the charity's public reporting of the work it does and the results it achieves.
n/r
DEMONSTRATED IMPACT
The demonstrated impact per dollar Ci calculates from available program information.
NEED FOR FUNDING
Charity's cash and investments (funding reserves) relative to how much it spends on programs in most recent year.
48%
CENTS TO THE CAUSE
For a dollar donated, after overhead costs of fundraising and admin/management (excluding surplus) 48 cents are available for programs.
My anchor
OVERVIEW
About Cystic Fibrosis Canada:
Cystic Fibrosis Canada is a three-star charity. It has an above-average results reporting score of A-. For every dollar donated, 48 cents are available to go towards the cause. Its reserve funds can cover just over two years of annual program costs.
Founded in 1960, Cystic Fibrosis Canada (CFC) aims to end cystic fibrosis by funding research for a cure and advocating for high-quality patient care. Cystic Fibrosis (CF) is an inherited disease that can cause severe damage to the lungs, digestive tract, and other organs. It involves uncontrolled mucus buildup in the body which can lead to nutrient deficiencies, chronic infections, and death in most patients. Cystic Fibrosis Canada states that CF is the most common fatal genetic disease affecting Canadian children and young adults. CFC runs four main programs: Research, Community Engagement, Healthcare, and Advocacy. In fiscal 2024 (year ended January), Cystic Fibrosis Canada spent $6.9m on its programs and grants.
Research was 42% of program spending. CFC’s research funding has resulted in many significant developments in CF research, including the discovery of the CF gene in 1989. In F2024, the charity invested nearly $3 million on new research initiatives aligned with CFC’s new Momentum research strategy.
Community Engagement was 26% of program spending. In 2021, CFC launched the Elevate program that invites members to participate in a range of opportunities. These include informing CFC’s mental health work and providing perspectives on gene therapy. In F2024, the Elevate program has 230 members.
Healthcare was 19% of program spending. In F2023, 286 people were enrolled in five observational clinics, and 184 people were enrolled in 18 interventional clinical trials. The information has not yet been updated for F2024.
Advocacy was 11% of program spending. Cystic Fibrosis Canada runs provincial and national advocacy campaigns to raise awareness and increase support for CF patients. In F2024, more than 1,800 people participated in a letter-writing campaign for coverage of the Trikafta drug.
The remaining 1% of program spending was allocated to other costs.
My anchor
Results and Impact
Cystic Fibrosis Canada advocates for provincial and federal government access to CF treatments like Trikafta. In October 2023, Health Canada approved Trikafta for use in those aged two and up, instead of six and up. In 2022, approximately 2,500 Canadians with CF were taking CFTR modulator therapies. That represents a 70% increase since 2021 and more than five times the number of Canadians taking CFTR modulators in 2018.
Cystic Fibrosis Canada’s clinical trials network has experienced significant growth over the past years. The most recent data CF CanACT data from F2023 shows that 60% of the Canadian CF population has direct access to clinical trials via CFC’s ten networks.
Cystic Fibrosis Canada has outstanding reporting on the trends and results of how cystic fibrosis diagnosis has changed in Canada dramatically since 2018 with new drug treatments. Learn more in CFC's 2022 Data Report.
While Ci highlights these key results, they may not be a complete representation of Cystic Fibrosis Canada’s results and impact. This charity is not yet rated on impact (n/r).
My anchor
Finances
In F2024, Cystic Fibrosis Canada received $12.4m in donations, down 3% from $12.7m in F2023. Administrative costs are 15% of revenues (less investment income) and fundraising costs are 37% of donations. For every dollar donated, 48 cents are available to go towards the cause. This is outside of Ci’s reasonable range.
In F2024, CFC spent $6.9m on its programs and grants which represents 47% of total revenues. The charity has $13.9m in reserve funds, which can cover just over two years of annual program costs.
In F2023, the charity used external fundraisers. Cystic Fibrosis Canada paid external fundraisers $55k to raise $42k. This means the cost of raising a dollar via external fundraisers was $1.33. At the time of this profile, the charity’s F2024 T3010 filing with the CRA had not been released yet. Ci is unaware if CFC used external fundraisers in F2024 and will update this profile once that information is released.
Profile updated on June 26, 2024 by Abby Stout.
Financial Review
Fiscal year ending January
|
2024 | 2023 | 2022 |
---|---|---|---|
Administrative costs as % of revenues | 15.1% | 11.4% | 9.4% |
Fundraising costs as % of donations | 36.9% | 36.4% | 36.0% |
Total overhead spending | 52.0% | 47.8% | 45.4% |
Program cost coverage (%) | 201.1% | 201.7% | 217.3% |
Summary Financial StatementsAll figures in $000s |
2024 | 2023 | 2022 |
---|---|---|---|
Donations | 12,399 | 12,719 | 11,192 |
Government funding | 0 | 0 | 694 |
Business activities (net) | 44 | 274 | 335 |
Investment income | 372 | (62) | (112) |
Other income | 2,016 | 639 | 1,058 |
Total revenues | 14,831 | 13,570 | 13,167 |
Program costs | 4,550 | 4,568 | 4,601 |
Grants | 2,371 | 2,314 | 1,623 |
Administrative costs | 2,178 | 1,553 | 1,249 |
Fundraising costs | 4,575 | 4,634 | 4,029 |
Total spending | 13,674 | 13,069 | 11,502 |
Cash flow from operations | 1,157 | 501 | 1,665 |
Capital spending | 0 | 0 | 0 |
Funding reserves | 13,921 | 13,879 | 13,526 |
Note: DEFERRED REVENUE: To report on a cash basis, Ci accounted for deferred revenue. This affected revenue by $961k in F2024, ($160k) in F2023, and $358k in F2022. INVESTMENT INCOME: Ci included investment income within revenue in the amount of $372k in F2024, ($62k) in F2023, and ($112k) in F2022. AMORTIZATION: Ci removed amortization from administrative costs on a pro-rata basis. This decreased total administrative costs by $26k in F2024, $13k in F2023, and $14k in F2022.
Salary Information
$350k + |
0 |
$300k - $350k |
0 |
$250k - $300k |
0 |
$200k - $250k |
1 |
$160k - $200k |
4 |
$120k - $160k |
5 |
$80k - $120k |
0 |
$40k - $80k |
0 |
< $40k |
0 |
Information from most recent CRA Charities Directorate filings for F2023
My anchor
Comments & Contact
Comments added by the Charity:
Charity Contact
This email address is being protected from spambots. You need JavaScript enabled to view it. Tel: 1-800-378-2233